Search Within

Center for Pancreatic Cancer Research

Formats
  1. Journal Article (5057)
  2. Meeting Abstract (2483)
  3. Book Section (225)
  4. Review (220)
  5. Editorial (135)
  6. Conference Paper (75)
  7. Correspondence (48)
  8. Research Letter (43)
  9. Miscellaneous (41)
  10. Guidelines (38)
  11. Book Whole (20)
Groups
  1. Department of Medicine (3942)
  2. Solid Tumor Oncology Division (3242)
  3. Surgery (3165)
  4. GSK Faculty (2910)
  5. Epidemiology and Biostatistics (2524)
  6. Gastrointestinal Oncology Service (2297)

More Groups

People
  1. Mithat Gonen (1034)
  2. William Jarnagin (911)
  3. Eileen O'Reilly (795)
  4. Michael D'Angelica (787)
  5. T Peter Kingham (620)
  6. David Kelsen (538)

More People

Years
  1. 2025 (286)
  2. 2024 (497)
  3. 2023 (523)
  4. 2022 (602)
  5. 2021 (555)
  6. 2020 (562)

More Years

Publications
  1. Journal of Clinical Oncology (927)
  2. Annals of Surgical Oncology (395)
  3. Cancer Research (226)
  4. International Journal of Radiation Oncology, Biology, Physics (219)
  5. Laboratory Investigation (209)
  6. Modern Pathology (191)

More Publications

Publishers
  1. American Society of Clinical Oncology (1002)
  2. Springer (840)
  3. Elsevier Inc. (757)
  4. Nature Publishing Group (632)
  5. American Association for Cancer Research (551)
  6. Elsevier Science, Inc. (510)

More Publishers

Results (8385)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
    Meeting Abstract

    Chan, J.; Geyer, S.; Zemla, T.; Knopp, M. V.; Behr, S. C.; Pulsipher, S.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EGFR evaluation in non-small cell lung cancer: An artificial intelligence approach to pre-molecular analysis
    Meeting Abstract

    Vanderbilt, C. M.; Nanda, S.; Singi, S.; Gupta, R.; Goldgof, G.; Ardon, O.; Elkrief, A.; Fuchs, T.; Campanella, G.; Hameed, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy of HB-200 in patients with detectable TTMV-HPV DNA after definitive treatment for HPV16 + HNSCC
    Meeting Abstract

    Ho, A. L.; Riaz, N.; Pfister, D.; Wong, R.; Lee, N.; Sherman, E. J.; Haque, S.; Ostrovnaya, I.; Wong, W.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Dunn, L.; Cracchiolo, J.; Ho, A. L.; Sherman, E. J.; Ganly, I.; Ghossein, R.; Cohen, M.; Wong, W.; Desilets, A.; Michel, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Park, W.; Kasi, A.; Spira, A. I.; Berlin, J. D.; Wang, J. S.; Herzberg, B.; Kuboki, Y.; Kitano, S.; Pelster, M.; Goldman, J. W.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
    Meeting Abstract

    Tsai, C.; An, J. A. R.; Cabel, L.; Brannon, A. R.; Moiso, E.; Gedvilaite, E.; Ahmed, M.; Loudon, L.; Weipert, C.; Chou, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Ng, K.; Ou, F. S.; Zemla, T.; McCleary, N.; Kalyan, A.; Shusterman, M.; Vijayvergia, N.; Wu, C.; Cohen, S. A.; Pulsipher, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • NALIRIFOX versus FOLFOX as first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): Real-world comparative overall (OS) survival analysis
    Meeting Abstract

    O'Reilly, E.; Li, J.; DerSarkissian, M.; Chang, R.; Cheng, M.; Yu, L.; Rane, D.; Zhang, L.; Xiao, Z.; Benzaghou, F.; more...
    Pharmacoepidemiology and Drug Safety (2024)

    Fulltext@MSK | Save
  • Role of PD-1hiFoxp3-CD4+tumor-infiltrating lymphocytes in the immunotherapy response
    Meeting Abstract

    Zappasodi, R.; Mangarin, L. M.; Martis, S.; Orlando, A.; Schad, S.; Wolchok, J. D.; Greenbaum, B.; Merghoub, T.
    Cancer Science (2024)

    Fulltext@MSK | Save